ArticleFrontiers in microbiology2026
Anaerobic sequencing batch reactor enhances short-chain fatty acids productivity while facilitating downstream processing.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaerobic fermentation (AF) emerged as a promising technology to produce short-chain fatty acids (SCFAs). However, downstream processing of SCFAs is often challenging and costly due to the complexity of AF effluents that present high solids content. Sequencing batch reactors (SBRs) promote effluent separation in two phases (solids and supernatant), which can be an advantage to facilitate SCFAs downstream processing. This work evaluated the performance of SBRs operational configuration at different hydraulic retention times (HRT) (20, 15 and 10 d). The maximum SCFAs concentration of 28.3 g/L was reached at HRT of 20 d, whereas the maximum bioconversion (60.7%) and productivity (1.8 g SCFAs /Ld) were reached at HRT of 10 d. Regardless of the HRT, the predominant SCFAs found at the steady state were butyric and acetic acids (> 70% w/w), in accordance with the detection of acetate and butyrate kinases in all cell lysates. The SBR configuration enabled a 1.3-fold increase in the SCFAs yield (g SCFAs/g TS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.